Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Canonical transient receptor potential channels promote cardiomyocyte hypertrophy through activation of calcineurin signaling.

Authors: Bush, EW  Hood, DB  Papst, PJ  Chapo, JA  Minobe, W  Bristow, MR  Olson, EN  McKinsey, TA 
Citation: Bush EW, etal., J Biol Chem. 2006 Nov 3;281(44):33487-96. Epub 2006 Sep 1.
Pubmed: (View Article at PubMed) PMID:16950785
DOI: Full-text: DOI:10.1074/jbc.M605536200

The calcium/calmodulin-dependent phosphatase calcineurin plays a central role in the control of cardiomyocyte hypertrophy in response to pathological stimuli. Although calcineurin is present at high levels in normal heart, its activity appears to be unaffected by calcium during the course of a cardiac cycle. The mechanism(s) whereby calcineurin is selectively activated by calcium under pathological conditions has remained unclear. Here, we demonstrate that diverse signals for cardiac hypertrophy stimulate expression of canonical transient receptor potential (TRPC) channels. TRPC consists of a family of seven membrane-spanning nonselective cation channels that have been implicated in the nonvoltage-gated influx of calcium in response to G protein-coupled receptor signaling, receptor tyrosine kinase signaling, and depletion of internal calcium stores. TRPC3 expression is up-regulated in multiple rodent models of pathological cardiac hypertrophy, whereas TRPC5 expression is induced in failing human heart. We demonstrate that TRPC promotes cardiomyocyte hypertrophy through activation of calcineurin and its downstream effector, the nuclear factor of activated T cells transcription factor. These results define a novel role for TRPC channels in the control of cardiac growth, and suggest that a TRPC-derived pool of calcium contributes to selective activation of calcineurin in diseased heart.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 10044019
Created: 2015-06-01
Species: All species
Last Modified: 2015-06-01
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.